{"id":"NCT03235479","sponsor":"Pfizer","briefTitle":"Safety and Efficacy Study in Adult Subjects With Acute Migraines","officialTitle":"BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-18","primaryCompletion":"2018-01-21","completion":"2018-01-26","firstPosted":"2017-08-01","resultsPosted":"2020-12-23","lastUpdate":"2023-02-16"},"enrollment":1485,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine, With or Without Aura"],"interventions":[{"type":"DRUG","name":"Rimegepant","otherNames":["BHV-3000"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rimegepant 75 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines","primaryOutcome":{"measure":"Percentage of Participants With Freedom From Pain at 2 Hours Post-dose","timeFrame":"2 hours post-dose","effectByArm":[{"arm":"Rimegepant 75 mg","deltaMin":19.2,"sd":null},{"arm":"Placebo","deltaMin":14.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0298"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":["39070853","36739511"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":546},"commonTop":[]}}